MX2011008060A - Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. - Google Patents
Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.Info
- Publication number
- MX2011008060A MX2011008060A MX2011008060A MX2011008060A MX2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A MX 2011008060 A MX2011008060 A MX 2011008060A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- treatment
- disorders
- compounds
- brain
- Prior art date
Links
- -1 Bicyclic amide Chemical class 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000000848 glutamatergic effect Effects 0.000 title 1
- 230000009782 synaptic response Effects 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 3
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000003417 Central Sleep Apnea Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010013647 Drowning Diseases 0.000 abstract 1
- 206010021133 Hypoventilation Diseases 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 208000004166 Obesity Hypoventilation Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010035004 Pickwickian syndrome Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 208000034972 Sudden Infant Death Diseases 0.000 abstract 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 230000003930 cognitive ability Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20664209P | 2009-02-02 | 2009-02-02 | |
| PCT/US2010/000255 WO2010087981A2 (en) | 2009-02-02 | 2010-01-29 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008060A true MX2011008060A (es) | 2011-09-09 |
Family
ID=42396261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008060A MX2011008060A (es) | 2009-02-02 | 2010-01-29 | Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2391621A4 (OSRAM) |
| JP (1) | JP2012516845A (OSRAM) |
| KR (1) | KR20110115139A (OSRAM) |
| CN (1) | CN102369201A (OSRAM) |
| AU (1) | AU2010208646A1 (OSRAM) |
| BR (1) | BRPI1005316A2 (OSRAM) |
| CA (1) | CA2751285A1 (OSRAM) |
| EA (1) | EA018994B1 (OSRAM) |
| IL (1) | IL214392A0 (OSRAM) |
| MX (1) | MX2011008060A (OSRAM) |
| SG (1) | SG173168A1 (OSRAM) |
| WO (2) | WO2010087981A2 (OSRAM) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT651746E (pt) * | 1992-07-24 | 2002-09-30 | Univ California | Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa |
| US20020099050A1 (en) * | 1993-07-23 | 2002-07-25 | Lynch Gary S. | Drugs that enhance synaptic responses mediated by AMPA receptors |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| WO1999021422A1 (en) * | 1997-10-27 | 1999-05-06 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| CA2685858C (en) * | 2007-05-17 | 2015-11-24 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| AU2008287445A1 (en) * | 2007-08-10 | 2009-02-19 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
-
2010
- 2010-01-29 AU AU2010208646A patent/AU2010208646A1/en not_active Abandoned
- 2010-01-29 SG SG2011054376A patent/SG173168A1/en unknown
- 2010-01-29 EA EA201101162A patent/EA018994B1/ru not_active IP Right Cessation
- 2010-01-29 BR BRPI1005316A patent/BRPI1005316A2/pt not_active IP Right Cessation
- 2010-01-29 WO PCT/US2010/000255 patent/WO2010087981A2/en not_active Ceased
- 2010-01-29 EP EP10736150A patent/EP2391621A4/en not_active Withdrawn
- 2010-01-29 MX MX2011008060A patent/MX2011008060A/es active IP Right Grant
- 2010-01-29 KR KR1020117019461A patent/KR20110115139A/ko not_active Withdrawn
- 2010-01-29 CA CA2751285A patent/CA2751285A1/en not_active Abandoned
- 2010-01-29 WO PCT/US2010/000254 patent/WO2010087980A2/en not_active Ceased
- 2010-01-29 CN CN2010800154033A patent/CN102369201A/zh active Pending
- 2010-01-29 JP JP2011547981A patent/JP2012516845A/ja active Pending
-
2011
- 2011-08-01 IL IL214392A patent/IL214392A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG173168A1 (en) | 2011-08-29 |
| WO2010087980A3 (en) | 2011-02-24 |
| EP2391621A2 (en) | 2011-12-07 |
| EA018994B1 (ru) | 2013-12-30 |
| EA201101162A1 (ru) | 2012-01-30 |
| WO2010087981A3 (en) | 2011-03-24 |
| WO2010087981A2 (en) | 2010-08-05 |
| CA2751285A1 (en) | 2010-08-05 |
| CN102369201A (zh) | 2012-03-07 |
| AU2010208646A1 (en) | 2011-09-01 |
| KR20110115139A (ko) | 2011-10-20 |
| BRPI1005316A2 (pt) | 2019-09-24 |
| IL214392A0 (en) | 2011-09-27 |
| WO2010087980A2 (en) | 2010-08-05 |
| EP2391621A4 (en) | 2012-07-25 |
| JP2012516845A (ja) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012430A (es) | Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas. | |
| SG163526A1 (en) | Bicyclic amides for enhancing glutamatergic synaptic responses | |
| MX2010002890A (es) | 1, 2, 3-triacin -4-onas sustituidas en la posicion 3 y 1, 3- pirimidinonas sustituidas en la posicion 3 para mejorar las respuestas sinapticas glutamatergicas. | |
| TN2009000278A1 (en) | 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| SI2349300T1 (sl) | Kombinacijska terapija za zdravljenje bolnikov z nevrološkimi motnjami in možganskim infarktom | |
| MX2009004071A (es) | Moduladores de bifenilsulfonilo y fenil-heteroarilsulfonilo del receptor de histamina h3 utiles para el tratamiento de trastornos relacionados con los mismos. | |
| TN2009000277A1 (en) | 3-substituted -[1,2,3]- benzotriazinone compound for enhancing glutamatergic synaptic reponses | |
| PL2318035T3 (pl) | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| EA202090043A1 (ru) | Диазабициклические замещенные имидазопиримидины и их применение | |
| DOP2011000138A (es) | Nuevos compuestos 578 | |
| MX2011011273A (es) | Derivados de isoxazol-pirazol. | |
| CR20220195A (es) | Inhibidores de adrenoreceptor adrac2 | |
| SV2009002917A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| Askenasy | Approaching disturbed sleep in late Parkinson's disease: first step toward a proposal for a revised UPDRS | |
| WO2008153958A3 (en) | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto | |
| JP2010529130A5 (OSRAM) | ||
| MX2011008060A (es) | Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas. | |
| MX2010008706A (es) | Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales. | |
| HUP0900231A2 (hu) | Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására | |
| EP2552473A4 (en) | METHOD FOR THE TREATMENT OF MORBUS PARKINSON AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN | |
| WO2007061741A3 (en) | Modulators of the h3 receptor useful for the treatment of disorders related thereto | |
| WO2011015646A3 (en) | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
| GT200900150A (es) | Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen. | |
| UA93306C2 (ru) | Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |